文献速递瓣膜外科先天性心脏病外科

婴幼儿二尖瓣置换:HALO临床试验五年结果

Mitral Valve Replacement in Infants and Children: Five-Year Outcomes of the HALO Clinical Trial.
PubMed 文献 · Ann Thorac Surg · 2024-05-14

多中心豁免研究评估15毫米St Jude机械二尖瓣在23例婴幼儿(平均7.8月龄,平均5.5kg)中的五年结果。6例死亡均发生在术后12个月内且与瓣膜无关,3例血栓需取出瓣膜,1年无出血率71.0%,1年和5年无死亡或瓣膜取出率均为71.0%。作者认为低分子肝素可能应避免作为主要抗凝。

要点

  • 23例婴幼儿接受15毫米St Jude机械二尖瓣置换,85%小于1岁,平均体重5.5kg。
  • 6例死亡均发生在术后12个月内,无瓣膜相关死亡;3例血栓需取出瓣膜。
  • 1年和5年无死亡或瓣膜取出率均为71.0%,1年无出血率71.0%。

核心结论

  • 在小儿严重二尖瓣病变需行二尖瓣置换时,15毫米St Jude机械二尖瓣提供满意的血流动力学。
  • 这些患者的死亡和并发症并非轻微。
  • 低分子肝素可能应避免作为主要抗凝。
  • 最终瓣膜更换不可避免。

研究设计与样本

  • 多机构研究器械豁免试验,2015年5月至2017年3月在15个中心纳入23例0.4至27.4个月(平均7.8个月;85%小于1岁)、体重2.9至10.9kg(平均5.5kg)的儿童,行15毫米St Jude机械二尖瓣置换(瓣环内45%,瓣环上55%)。
  • 21例(91%)既往接受过心脏手术,随访至死亡、瓣膜取出或术后5年,完成率100%。

主要发现

  • 6例死亡均发生在术后12个月内,无瓣膜相关死亡。
  • 4例需要起搏器(瓣环上2例,瓣环内2例)。
  • 3例发生血栓需取出瓣膜,分别在术后13、21和35天;其中2例使用低分子肝素抗凝,第3例有因子V Leiden缺乏。
  • 二尖瓣置换后4个月内发生5例非致命性出血并发症(1年无出血率71.0%)。
  • 1年和5年无死亡或瓣膜取出率均为71.0%。

关键数值与推荐

  • 1年无出血率71.0%。
  • 1年和5年无死亡或瓣膜取出率均为71.0%。

临床怎么用

  • 作者认为低分子肝素可能应避免作为主要抗凝。
  • 作者指出最终瓣膜更换不可避免。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Repair is preferable for children with mitral valve disease, but mitral valve replacement (MVR) is occasionally necessary. This report presents the results of a multiinstitutional Investigational Device Exemption trial of the 15-mm St Jude (SJM) mechanical mitral valve (Abbott Structural Heart). METHODS: From May 2015 to March 2017, 23 children aged 0.4 to 27.4 months (mean, 7.8 months; 85% <1 year) weighing 2.9 to 10.9 kg (mean, 5.5 kg) at 15 centers underwent MVR with a 15-mm SJM mechanical mitral valve (intraannular, 45%; supraannular, 55%). A total of 21 (91%) of the children had undergone previous cardiac operations. Follow-up until death, valve explantation, or 5 years postoperatively was 100% complete. RESULTS: There were 6 deaths, all in the first 12 months; no death was valve related. Four patients required a pacemaker (2 supraannular, 2 intraannular). Three patients had thrombosis requiring valve explantation at 13, 21, and 35 days postoperatively. Two of these 3 patients were receiving low-molecular-weight heparin for anticoagulation, and the third had factor V Leiden deficiency. There were 5 nonfatal bleeding complications within 4 months of MVR (1-year freedom from bleeding, 71.0%). The 1- and 5-year freedom from death or valve explantation was 71.0%. CONCLUSIONS: In small children with severe mitral valve disease requiring MVR, the 15-mm SJM mechanical mitral valve provides satisfactory hemodynamics. Mortality and complications in these patients are not trivial. Low-molecular-weight heparin likely should be avoided as primary anticoagulation. Eventual valve replacement is inevitable.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Shaw FR, Kogon B, Chen J, et al. Mitral Valve Replacement in Infants and Children: Five-Year Outcomes of the HALO Clinical Trial. Ann Thorac Surg. 2024. PMID: 38750684. doi:10.1016/j.athoracsur.2024.04.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。